Amitriptyline is FDA approved medication to treat depression in adults.
The non-FDA approved indications are anxiety, post-traumatic stress disorder, insomnia, chronic pain (diabetic neuropathy, fibromyalgia), irritable bowel syndrome, interstitial cystitis (bladder pain syndrome), migraine prophylaxis, postherpetic neuralgia, and sialorrhea.
Amitriptyline is in the tricyclic antidepressant (TCA) drug classification and acts by blocking the reuptake of both serotonin and norepinephrine neurotransmitters. The three-ring central structure, along with a side chain, is the basic structure of tricyclic antidepressants. Amitriptyline is a tertiary amine and has strong affinities for alpha-adrenergic, histamine (H1), and muscarinic (M1) receptors. It is more sedating and has increased anticholinergic properties compared to other TCAs.
Like other antidepressants, the onset of therapeutic action typically begins at approximately 2 to 4 weeks.
Amitriptyline administration comes in various forms, the most common being oral form. The initial dose recommended for depression is 25 mg/day at bedtime, as it can be sedating. For off-label use such as for chronic pain, therapy can initiate at a much lower dose of 10 to 20 mg/day. It can be increased by 25 mg every 3 to 7 days, with a maximum of 150 to 300 mg/day. If the dose needs to be adjusted, it is preferable to change the dose at bedtime. Once the patient is stable, amitriptyline should be continued for three months or longer to prevent relapse of depression. In cases of therapy cessation, the clinician should gradually taper to avoid withdrawal.
Amitriptyline is not FDA approved for pediatric depression. The recommendation is to start with a lower dosage (around 10 mg/day) in the pediatric and geriatric population.
Its half-life is 10 to 28 hours, and it gets metabolized to nortriptyline. Its metabolism is primarily by CYP3A and CYP2C19.
Amitriptyline administration can also via the intramuscular route (peak concentration occurs within 2 to 12 hours of administration), and an intravenous route is another one.
The most commonly encountered side effects of amitriptyline include weight gain, gastrointestinal symptoms like constipation, xerostomia, dizziness, headache, and somnolence.
The following is a list of other adverse effects including serious side effects of amitriptyline:
1. Secondary to its alpha-adrenergic receptor blockade, it can cause orthostatic hypotension, dizziness, and sedation. It can also cause heart rate variability, slow intracardiac conduction, induce various arrhythmias, and cause QTc (corrected QT) prolongation.
2. Anticholinergic side effects include blurred vision, dry mouth, urinary retention, tachycardia, acute angle glaucoma, confusion, and delirium.
3. Antihistamine side effects secondary to its H1 receptor property include sedation, increased appetite, weight gain, confusion, and delirium.
4. Amitriptyline can lower the seizure threshold, and it should be used cautiously in patients with a history of seizure disorder. Its seizure threshold reducing effect is dose-dependent, seizure rate is 1 to 4% at doses of 250 to 450mg/day.
5. It is known to cause abnormalities in liver function tests in 10 to 20% of patients. It is uncommon for the liver function test to be over three times the upper limit of normal. Usually, the effect on the liver is mild, asymptomatic, transient, and reverses with discontinuation. It rarely causes acute liver injury.
6. It can also cause impaired arousal, the risk of bone fracture, tremor, and (rare) bone marrow suppression.
7. In adolescents and young adults (ages less than 24 years), it can increase the risk of suicidal ideation and behavior (rarely). The risk is very low, but the patient and families require education regarding these risks.
8. As an antidepressant, amitriptyline can rarely induce mania. Some of the risk factors that can predict amitriptyline inducing mania are a history of bipolar disorder, family history of mania, pharmacologically induced hypomania.
Contraindication considerations are one of the most critical aspects while administering a drug to a patient. The following are significant considerations for amitriptyline:
1. Hypersensitivity reactions are an essential consideration. Amitriptyline is contraindicated in patients with hypersensitivity to the drug or any of its inactive ingredients.
2. Amitriptyline should not be used if there is a history of QTc prolongation, arrhythmias, recent myocardial infarction, or heart failure.
3. Its use requires caution in patients with angle-closure glaucoma, urinary retention, seizures.
4. Do not use with MAOI (monoamine oxidase inhibitors) and also within 14 days use of MAOIs.
5. It is essential to keep into account various drug-drug interactions. Considering amitriptyline causes QTc prolongation, the use of other drugs that prolong QTc can lead to cardiac problems, including arrhythmias. The following medications can increase QTc- astemizole, cisapride, disopyramide, ibutilide, indapamide, pentamidine, pimozide, procainamide, quinidine, sotalol, terfenadine.
6. Some drugs, when used along with amitriptyline, may cause an increase in serotonin levels, such drugs include isocarboxazid, phenelzine, procarbazine, safinamide, selegiline, tranylcypromine. These drugs can cause serotonin syndrome.
7. Amitriptyline gets metabolized from CYP3A4. Several drugs alter the activity of CYP3A4, and thus dose should be cautiously regulated, as well as the entire patient medication regimen checked for CYP3A4 inducers and inhibitors.
8. Lower doses are advisable in renal and hepatic impairment.
9. Before elective surgery, the recommendation is to discontinue amitriptyline because of its possible interaction with anesthesia and as it may increase the risk of arrhythmia.
In patients with a history of cardiac problems or patients over 50 years of age should have a baseline electrocardiogram.
While a patient is on amitriptyline, one should monitor for an increase in suicidality and unusual behavior changes, especially during the first 1 to 2 months of starting medication or during periods of dosage adjustment.
Amitriptyline toxicity is measurable by a level of over 5mg/kg. The clinical features of amitriptyline toxicity include:
1. Neurological symptoms include sedation, seizure, coma.
2. Cardiac symptoms include tachycardia, hypotension, conduction abnormalities include QTc prolongation.
3. Anticholinergic symptoms include dilated pupils, dry mouth, decreased (or absent) bowel sounds, urinary retention.
Amitriptyline toxicity can be serious and even fatal. In treating the toxicity, it is imperative to stabilize the patient, and the patient may need admission to the ICU for monitoring. The most important steps include - protecting the airways, breathing, and stabilizing circulation. Some patients may need tracheal intubation; if required, administer supplemental oxygen. If the patient is hypotensive, an IV bolus of isotonic crystalloid is a therapeutic option. If the patient remains hypotensive despite fluid resuscitation, vasopressors are the next choice. If QRS exceeds 100 msec, intravenous sodium bicarbonate is the appropriate intervention as it is cardioprotective (it increases extracellular sodium concentration) and diminishes the effect of amitriptyline on the cardiac membrane, which results in less blockage of the sodium channel.) Activated charcoal can also be given within two hours of amitriptyline ingestion to prevent gastrointestinal absorption. Seizures secondary to overdose are treatable with diazepam or lorazepam.
Amitriptyline is a tricyclic antidepressant that is FDA approved to treat depression in adults. It is also used off label to treat chronic pain syndrome, anxiety, and insomnia. It has a considerable side effect profile and is no longer commonly used as a first-line agent to treat depression. It may be useful for patients who have insomnia, severe depression, treatment-resistant depression, and patients with comorbid chronic pain syndromes. Patients on amitriptyline can have anticholinergic, antihistaminic, and alpha-adrenergic blocking effects. It may not be appropriate for patients with cardiac problems. It has many drug interactions, which can increase the risk of arrhythmias and serotonin syndrome. Toxicity can be life-threatening, and patients will need to be stabilized and monitored closely. Providers also need to know the increased risk of suicidality in children, adolescents, and young adults, which will require discussion with families.
When a clinician determines to start a patient on amitriptyline, they should consult a pharmacist to verify the absence of drug-drug interactions, which in the case of amitriptyline, can be significant. Nursing can provide medication counseling, evaluate patient compliance, and monitor for side effects on follow-up visits. If the nurse has any concerns, they should be reported to the clinician promptly. While amitriptyline is not a common therapeutic choice any longer, when necessary, it can be effective if the interprofessional team collaborates in therapeutic decisions, the patient can achieve an optimal outcome with minimal adverse events. [Level V]
|||Dopheide JA, Recognizing and treating depression in children and adolescents. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2006 Feb 1; [PubMed PMID: 16434782]|
|||Radley DC,Finkelstein SN,Stafford RS, Off-label prescribing among office-based physicians. Archives of internal medicine. 2006 May 8; [PubMed PMID: 16682577]|
|||Gillman PK, Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British journal of pharmacology. 2007 Jul; [PubMed PMID: 17471183]|
|||Venkatakrishnan K,Schmider J,Harmatz JS,Ehrenberg BL,von Moltke LL,Graf JA,Mertzanis P,Corbett KE,Rodriguez MC,Shader RI,Greenblatt DJ, Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. Journal of clinical pharmacology. 2001 Oct; [PubMed PMID: 11583471]|
|||Deisenhammer EA,Whitworth AB,Geretsegger C,Kurzthaler I,Gritsch S,Miller CH,Fleischhacker WW,Stuppäck CH, Intravenous versus oral administration of amitriptyline in patients with major depression. Journal of clinical psychopharmacology. 2000 Aug; [PubMed PMID: 10917402]|
|||Güloglu C,Orak M,Ustündag M,Altunci YA, Analysis of amitriptyline overdose in emergency medicine. Emergency medicine journal : EMJ. 2011 Apr; [PubMed PMID: 20923818]|
|||Nishimura T,Maruguchi H,Nakao A,Nakayama S, Unusual complications from amitriptyline intoxication. BMJ case reports. 2017 Oct 10; [PubMed PMID: 29018010]|
|||Voican CS,Corruble E,Naveau S,Perlemuter G, Antidepressant-induced liver injury: a review for clinicians. The American journal of psychiatry. 2014 Apr; [PubMed PMID: 24362450]|
|||Rabenda V,Nicolet D,Beaudart C,Bruyère O,Reginster JY, Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2013 Jan; [PubMed PMID: 22638709]|
|||Sabah KMN,Chowdhury AW,Islam MS,Saha BP,Kabir SR,Kawser S, Amitriptyline-induced ventricular tachycardia: a case report. BMC research notes. 2017 Jul 14; [PubMed PMID: 28709467]|
|||Yoshida A,Hisatome I,Nawada T,Sasaki N,Taniguchi S,Tanaka Y,Manabe I,Ahmmed GU,Sato R,Mori A,Hattori K,Ueta Y,Mitani Y,Watanabe M,Igawa O,Fujimoto Y,Shigemasa C, Amitriptyline inhibits the G protein and K channel in the cloned thyroid cell line. European journal of pharmacology. 1996 Sep 19; [PubMed PMID: 8891586]|
|||Sasyniuk BI,Jhamandas V,Valois M, Experimental amitriptyline intoxication: treatment of cardiac toxicity with sodium bicarbonate. Annals of emergency medicine. 1986 Sep; [PubMed PMID: 3017159]|
|||Ramasubbu B,James D,Scurr A,Sandilands EA, Serum alkalinisation is the cornerstone of treatment for amitriptyline poisoning. BMJ case reports. 2016 Apr 11; [PubMed PMID: 27068728]|
|||Hultén BA,Adams R,Askenasi R,Dallos V,Dawling S,Heath A,Volans G, Activated charcoal in tricyclic antidepressant poisoning. Human toxicology. 1988 Jul; [PubMed PMID: 3410479]|
|||Montgomery SA, Suicide and antidepressants. Annals of the New York Academy of Sciences. 1997 Dec 29; [PubMed PMID: 9616807]|